Abstract
Schizophrenia has been historically characterized by the presence of positive symptomatology, however, decades of research highlight the importance of cognitive deficits in this disorder. At present, cognitive impairments remain one of the most important unmet therapeutic needs in schizophrenia. The prefrontal cortex (PFC) controls a large number of higher brain functions altered in a variety of psychiatric disorders, including schizophrenia. Histological studies indicate the presence of a large proportion of PFC neurons expressing monoaminergic receptors sensitive to the action of current atypical antipsychotics. Functional studies also show that these medications act at PFC level to increase dopamine neurotransmission in the mesocortical pathway. Here we focus on monoaminergic molecular targets that are actively being explored as potential therapeutic agents in the basic and clinical cognitive neuroscience research, to support the development of co-treatments used in conjunction with antipsychotic medications. These targets include dopamine and serotonin receptors in the prefrontal cortex, as well as elements of the noradrenergic system.
Keywords: Antipsychotic drugs, cognitive deficits, monoamines, prefrontal cortex, schizophrenia.
Current Topics in Medicinal Chemistry
Title:Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review
Volume: 12 Issue: 21
Author(s): Mercè Masana, Noemí Santana, Francesc Artigas and Analía Bortolozzi
Affiliation:
Keywords: Antipsychotic drugs, cognitive deficits, monoamines, prefrontal cortex, schizophrenia.
Abstract: Schizophrenia has been historically characterized by the presence of positive symptomatology, however, decades of research highlight the importance of cognitive deficits in this disorder. At present, cognitive impairments remain one of the most important unmet therapeutic needs in schizophrenia. The prefrontal cortex (PFC) controls a large number of higher brain functions altered in a variety of psychiatric disorders, including schizophrenia. Histological studies indicate the presence of a large proportion of PFC neurons expressing monoaminergic receptors sensitive to the action of current atypical antipsychotics. Functional studies also show that these medications act at PFC level to increase dopamine neurotransmission in the mesocortical pathway. Here we focus on monoaminergic molecular targets that are actively being explored as potential therapeutic agents in the basic and clinical cognitive neuroscience research, to support the development of co-treatments used in conjunction with antipsychotic medications. These targets include dopamine and serotonin receptors in the prefrontal cortex, as well as elements of the noradrenergic system.
Export Options
About this article
Cite this article as:
Masana Mercè, Santana Noemí, Artigas Francesc and Bortolozzi Analía, Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review, Current Topics in Medicinal Chemistry 2012; 12 (21) . https://dx.doi.org/10.2174/1568026611212210008
DOI https://dx.doi.org/10.2174/1568026611212210008 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pin1: A New Outlook in Alzheimers Disease
Current Alzheimer Research Effects of the KIBRA Single Nucleotide Polymorphism on Synaptic Plasticity and Memory: A Review of the Literature
Current Neuropharmacology Bidirectional Nature of Cardiovascular and Kidney Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Evaluation of Insulin Resistance Induced Brain Tissue Dysfunction in Obese Dams and their Neonates: Role of Ipriflavone Amelioration
Combinatorial Chemistry & High Throughput Screening Resilience to Alzheimer's Disease: The Role of Physical Activity
Current Alzheimer Research Advances in Studies on Stroke-Induced Secondary Neurodegeneration (SND) and Its Treatment
Current Topics in Medicinal Chemistry Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine The Role of Metabolizing Enzymes and Transporters in Antiretroviral Therapy
Current Topics in Medicinal Chemistry Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Current Alzheimer Research GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment
Current Drug Targets Drug Choices and Advancements for Managing Depression in Parkinson's Disease
Current Neuropharmacology Targeting of Nuclear Factor-κB and Proteasome by Dithiocarbamate Complexes with Metals
Current Pharmaceutical Design Editorial [Hot Topic: Exploring the Links between Obesity and Alzheimers Disease (Guest Editor: Suzana S. Petanceska) ]
Current Alzheimer Research Update on the Pharmacological Treatment of Alzheimers Disease
Current Neuropharmacology The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews The Failure of Immunomodulation Therapy in Heart Failure: Does the Statins “Paradigm” Prove the Rule?
Current Vascular Pharmacology Cerebrovascular Changes and Neurodegeneration Related to Hyperlipidemia: Characteristics of the Human ApoB-100 Transgenic Mice
Current Pharmaceutical Design Hypoxic Preconditioning Ameliorates Amyloid-β Pathology and Longterm Cognitive Decline in AβPP/PS1 Transgenic Mice
Current Alzheimer Research Amaranth: A Pseudo-Cereal with Nutraceutical Properties
Current Nutrition & Food Science Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
Current Alzheimer Research